{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
ACADIA Pharmaceuticals, Inc.
Is ACADIA Pharmaceuticals, Inc. technically bullish or bearish?
As of September 12, 2025, ACADIA Pharmaceuticals has a mildly bullish trend, supported by positive weekly and monthly MACD indicators and strong year-to-date performance of 34.90%, despite some caution from a mildly bearish KST and underperformance in the 3- and 5-year periods.
Is ACADIA Pharmaceuticals, Inc. overvalued or undervalued?
As of August 6, 2025, ACADIA Pharmaceuticals is considered attractive but overvalued compared to peers, with a P/E ratio of 16 and strong one-year returns of 51.59%, although it lags behind the S&P 500's three-year return of 70.41%.
ACADIA Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance
ACADIA Pharmaceuticals, Inc. has recently revised its evaluation amid changing market dynamics. The stock has shown strong performance over the past year, significantly outperforming the S&P 500. Technical indicators present mixed signals, reflecting both bullish and bearish trends in the short term.
Is ACADIA Pharmaceuticals, Inc. technically bullish or bearish?
As of June 27, 2025, ACADIA Pharmaceuticals has a bullish technical trend supported by positive daily moving averages and a bullish weekly MACD, although caution is advised due to a mildly bearish weekly OBV.
Is ACADIA Pharmaceuticals, Inc. overvalued or undervalued?
As of November 6, 2024, ACADIA Pharmaceuticals is considered undervalued with a P/E ratio of 16, strong operational efficiency indicated by a 92.98% ROCE, and has outperformed the S&P 500 with a 46.93% return over the past year, making it a more favorable investment compared to its peers.
Is ACADIA Pharmaceuticals, Inc. technically bullish or bearish?
As of June 2, 2025, ACADIA Pharmaceuticals is in a bullish trend with moderate strength, supported by a bullish MACD and daily moving averages, despite some short-term weakness indicated by the weekly RSI.
Who are in the management team of ACADIA Pharmaceuticals, Inc.?
As of March 2022, the management team of ACADIA Pharmaceuticals, Inc. includes Dr. Stephen Biggar (Independent Chairman), Mr. Stephen Davis (CEO), and several independent directors: Ms. Elizabeth Garofalo, Mr. Julian Baker, Ms. Laura Brege, Mr. James Daly, and Dr. Edmund Harrigan. They oversee the company's strategic direction and operations.
What does ACADIA Pharmaceuticals, Inc. do?
ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for central nervous system disorders, with a recent market cap of approximately $3.82 billion and net sales of $244 million. The company has a P/E ratio of 16.00 and no dividend yield.
How big is ACADIA Pharmaceuticals, Inc.?
As of Jun 18, ACADIA Pharmaceuticals, Inc. has a market capitalization of $3.82 billion, with net sales of $996.28 million and a net profit of $228.89 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
